Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PST 611

Next Previous
Drug Profile

PST 611

Alternative Names: EYS-611; PST-611

Latest Information Update: 11 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eyevensys
  • Developer Eyevensys; PulseSight Therapeutics
  • Class Antiglaucomas; Eye disorder therapies; Gene therapies; Neuroprotectants
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa
  • New Molecular Entity No

Highest Development Phases

  • Phase I Dry macular degeneration
  • Preclinical Glaucoma; Retinitis pigmentosa

Most Recent Events

  • 31 Jul 2025 Phase-I clinical trials in Dry macular degeneration in France (Intraocular) (NCT07024732)
  • 14 Jan 2025 PulseSight Therapeutics plans a phase I trial for Dry age-related macular degeneration in France, in July 2025 (NCT07024732)
  • 14 Jan 2025 PulseSight Therapeutics submits CTA application to the Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM) for a phase I trial (PST-611-CT1)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top